This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (10)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Who Shall Live and Who Shall Die?

Jason K. Rivers, MD, FRCPC; Vincent C. Ho, MD, FRCPC

Arch Dermatol. 1992;128(4):537-542.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In 1991, it was estimated that, in the United States, there were over 6500 deaths from malignant melanoma (MM). There are many things about the biology of MM and its interaction with the host's immune system that we do not understand. Yet, we have come a long way—5-year survival has increased from 43% during the 1930s to greater than 80% by the mid-1980s. Many MM investigators have sought the Holy Grail, a factor or group of factors that would allow for the accurate prognostication of disease behavior in the majority of patients.

The study of prognostic factors is important not only for a better understanding of the biologic behavior of MM but also for the optimal management of these patients and for the design and evaluation of therapeutic trials. In the past two decades, many clinical, histologic, immunologic, and cytometric factors have been reported to influence the prognosis of patients . . . [Full Text PDF of this Article]

Author Affiliations
University of British Columbia Division of Dermatology 855 W 10th Ave Vancouver, British Columbia Canada V5Z 1L7

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?